Daily News Analysis

Research linked Incentive scheme

stylish_lining

Research linked Incentive scheme

Why in the News?

The Ministry of Science and Technology has written to the Finance Ministry to introduce a Research Linked Incentive (RLI) scheme for the Pharma sector in the upcoming budget of 2024-25.

What is Research linked Incentive scheme?

  1. The RLI scheme has been envisaged on the lines of production-linked incentive (PLI) scheme, to give stimulus to research and development in the field of Science and Technology (S&T).
  2.  The incentives provided to the companies shall total an outlay of Rs. 100 Crore per year, with incremental annual spending in the forthcoming years.
  3. RLI also incorporates policy interventions to harness India’s inherent potential.
  4. The scheme shall operate in addition to the existing incentive R&D schemes available for the Pharma and biotech companies operating in India.

Possible benefits of the scheme:

  1. The incentives provided by the scheme shall enable firm push to Research and development to boost Innovation, that can help to improve India’s ranking in the Global innovation Index (GII) further.

 

 

 

 

  1. Promotes innovation in emerging fields of S&T:
    1. Electric vehicles (EV)
    2. Hydrogen and renewable energy
    3. Sustainable technologies
    4. Artificial intelligence (AI) based smart technologies involving Machine Learning
    5. Semiconductor designing and manufacturing.
  2. Research-linked incentives given sector-specific enables development of sustainable and green technologies in the future.
  3. The scheme shall enable India to shift away from a low-value, high-volume player to a high-value, high-volume player in the global pharma market.

About:

Research & Development in the Pharma sector:

  1. The Pharma R&D processes involves:
    1. Pre-clinical research
    2. Discovery of innovative drugs
    3. Clinical trials of prescription drugs
    4. Preparation and submission of applications for Food and Drug Administration or FDA approval
    5. Designing production processes for the new product
    6. Clinical testing of a new drug against an existing drug to showcase the benefits of the new drug.
    7. Additional clinical trials after a new drug reaches the market
      1. for safety monitoring
      2. Detection of additional side effects that may not have been observed in earlier trials during development
    8. Improvements over existing prescription drugs by developing new dosages and delivery systems and testing for additional potential uses
  2. India’s R&D in Pharma sector:
    1. The gestation period for translation of concept to market may take about 10-15 years, with a >90% attrition rate in the Indian pharma industry.
    2. The need for a early innovation and a cushion for handling the risk of capital needs given the high failure rate stresses the importance of incentives in R&D sector in India.
    3. The average pharma industry funding continues to be around 10%, compared to 15-20% for most large innovators globally. 
    4. Though government grants are provided especially from BIRAC (e.g., the Biotechnology Ignition Grant) and MeiTY, which accounts for about Rs 5-50 lakhs over 6-18 months, it remains largely insufficient for the entire development cycle of drugs.
    5. The R&D Expenditure of India stands at 0.8% of the GDP, way lower than the developed and emerging economies of the world.

 

 
 


UNESCO: R&D intensity as a percentage of GDP (2018)

 

 

 

Visakhapatnam Declaration on e-Governance

The Visakhapatnam Declaration on e-Governance marks a significant step in the development of digital governance in India, emphasizing inclusive, transparent, and citizen-centric practices. Adopted
Share It

Defamation in India

Recently, a Supreme Court judge raised concerns about the increasing misuse of defamation laws by political figures and private individuals to settle personal and political disputes. The judge sug
Share It

Simultaneous Elections

India's ongoing debate about simultaneous elections or the One Nation, One Election concept has gained momentum, with experts like Arvind Panagariya, Chairman of the 16th Finance Commission, e
Share It

Shanghai Cooperation Organisation (SCO) 2025 Summit

The 2025 SCO Heads of State Summit was held in Tianjin, China, marking a significant moment for the organization’s expanding role on the global stage. Key Highlights: Terrorism:
Share It

Production Gap Report 2025

The Production Gap Report 2025 reveals a troubling trend: many countries are planning to increase fossil fuel production well beyond the levels needed to limit global warming to 1.5°C as per t
Share It

India's Roadmap for Fusion Power

India's Institute for Plasma Research (IPR) in Gandhinagar has recently proposed a comprehensive roadmap for the development of fusion power, marking a significant leap towards harnessing fusi
Share It

Dhvani Missile

India's Defence Research and Development Organisation (DRDO) is on the verge of a historic milestone with the upcoming test of Dhvani, a next-generation hypersonic missile that is set to prope
Share It

Global Innovation Index (GII) 2025

India has made remarkable strides in the field of innovation, moving up from 48th position in 2020 to 38th in 2025 among 139 global economies, according to the World Intellectual Property Organiza
Share It

Critical Minerals

India’s first auction of deep-sea blocks for the extraction of critical minerals has been delayed indefinitely after receiving a poor response from bidders. This auction was expected to be a
Share It

CAG Report on States’ Fiscal Health

The Comptroller and Auditor General of India (CAG) has released its first decadal analysis on the fiscal health of 28 Indian states, revealing significant concerns over the increasing public debt.
Share It

Newsletter Subscription


ACQ IAS
ACQ IAS